Uncategorized

Bega Group (ASX: BGA), Australia’s largest locally owned food group, has issued a warning stating that escalating dairy prices could result in a substantial non-cash impairment of up to $180 million. This impairment is expected to push the company into a statutory loss for the year ending on June 30. In an announcement made to […]

BHP Group (ASX:BHP) CEO Mike Henry cautions against excessive government intervention in global critical minerals supply chains, emphasising the importance of international cooperation and competition to effectively accelerate the energy transition and combat climate change. At noon, the S&P/ASX 200 is 0.59 per cent higher at 7,120.70. The SPI futures are pointing to a rise

INOVIQ (ASX:IIQ) has announced excellent results from an independent clinical validation study of the company’s SubB2M/CA15-3 test for breast cancer detection. CEO Dr Leearne Hinch said: “Our blood test detected all-stages of breast cancer with 81% sensitivity and 93% specificity, outperforming a leading CA15-3 test.” Shares are trading 19 per cent higher at 60 cents.

Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow discusses promising results in the company’s lead therapy for glioblastoma, and the timeline for the recently launched Phase 1b trial. Tim McGowen: Today we’re talking with Chimeric Therapeutics (ASX:CHM). Market cap of around $16m. We have with us the CEO and Managing Director, Jennifer Chow.

The Nasdaq Composite slumped on Monday as investors sold shares of technology companies that have outperformed this year and the final trading week of the first half commenced. The Nasdaq shed 1.16 per cent to settle at 13,335.78, while the S&P 500 lost 0.45 per cent to close at 4,328.82. The Dow Jones Industrial Average

Metcash (ASX:MTS) may have reported record annual sales and earnings for the year ending 30 April, but closer examination of the results reveals warning signs that cast doubt on the initial 9% surge in the retailer’s share price on Monday. By mid-afternoon, the early bounce had halved to just over 4% as investors scrutinized the

Shares in Element 25 (ASX:E25), a prominent manganese miner and explorer, experienced a significant surge of 23% on Monday following the announcement of a momentous supply contract with the renowned US car manufacturer, General Motors (GM). The contract, anticipated to be a multi-million dollar agreement, marks a substantial milestone in a project with an estimated